Choose Broker

Step 1
Choose a broker


Please enter your User ID and Password to place trade

Share or CFD

Step 2
Select the investment product you wish to purchase

OR

Share

Purchasing shares in a company buys you part ownership of that company. You're given the right to vote on who manages the company and receive a portion of company profits through the distribution of dividends.

Example: If a share price quote is $25, then that means one share is valued at $25.

Note: Shares are also referred to as stocks, equities and securities.

CFD

Is an abbreviation for "Contract for Difference". A CFD is a 'derivative' that is derived from the underlying value of the share price. A CFD’s allow you to go long (buy the CFD) or go short (sell the CFD).

CFD's give you leverage.

Example: Buying a CFD in XYZ provides you with an opportunity to purchase the shares at a variable rates such as 10 to 1 ratio instead of the full upfront share value cost i.e. paying $1,000 instead of $10,000.

Because CFDs are traded on margin, you must maintain the minimum margin level at all times.

Note: CFD’s are not recommended for novice traders.

Order Type

Step 3
Select your type of market order


Market Order

This is a type of order that instructs to buy or sell immediately at the best price available.

Limit Order

An order placed to buy or sell a set number of shares at a specified price or better.

Stop Order

This is an order that is executable once a set price has been reached. Once the order surpasses a particular point the order becomes a market order.

Stop Limit Order

An order placed that will be executed at a specific price or better after a given stop price has been reached. Therefore it combines the feature of a stop order with those of a limit order.

Order Period

Step 4
Select the time period that you want your trade to be live/active for.


G.T.C

Stands for good till cancelled. This means once the order is placed, the order will remain in place until someone cancels the order.

Day order

An order that if not executed, will stand until the end of the trading day.

One week

An order that will stand for a full week from the time it is placed, and then be automatically cancelled at the end of this period if it has not been executed.

One month

An order that if not executed, will stand for a full month.

End of week

An order that if not executed, will stand to the end of the trading week.

End of month

An order that if not executed, will stand to the end of the trading month.

End of year

An order that if not executed, will stand to the end of the year.

Quantity

Step 5
Select the value or quantity of how many shares you want to buy

Shares
@
$

Brokerage Fee: Please select broker first to calculate brokerage*.

Nominal Value:
$71.50 AUD

Risk Management

Step 6
Select what alarms (automatic exits) you want to protect both your investments and your profits.

Take Profit
$
OR
%
Stop Loss
$
OR
%
Trailing Stop Loss
%

Take Profit

Take-profit orders are used to lock in profits in the event the rate moves in a favorable direction. For example....

Stop Loss

Take-profit orders are used to lock in profits in the event the rate moves in a favorable direction. For example....

Trailing Stop Loss

Take-profit orders are used to lock in profits in the event the rate moves in a favorable direction. For example....

Confirm

Confirm
Please confirm your order

Buy -
Order Type -
Price -
Order Period -
Brokerage 8.00 AUD
Nominal Value -
Take Profit -
Stop Loss -
Trailing Stop Loss -
Trade Date -
There was a problem with your trade ticket. Please try again.
There was a problem submitting your trade ticket. Please try again in a minute.

Order Placed Successfully


Exit Orderpad        Place another trade
Current Price{{movement}} {{quote.Last.toFixed(3) == 0.000 ? quote['CF CLOSE'].toFixed(3) : quote.Last.toFixed(3)}} (20 minute delay)
Today's Change ${{quote['Net Change'].toFixed(3)}} ({{quote['% Change']}}%) Market is currently: {{quote['Price Qualifier Code'] == "OPN" ? "OPEN" : "CLOSED"}}
Open {{quote['Opening Price'].toFixed(3)}} Prev Close {{quote['Historic Close'].toFixed(3)}}
Today's High {{quote["Today's High"].toFixed(3)}} Today's Low {{quote["Today's Low"].toFixed(3)}}
Broker Consensus

No Data Available

  • Sell
  • Reduce
  • Hold
  • Buy
  • Strong Buy

Mesoblast Limited (MSB)
is a publicly listed company on the Australian Securities Exchange (ASX).


{{businessSummary}}

1 Day
Chart Type
Themes
Select Tool
Fill:
Line:
Axis Label:
  • Open:
  • High:
  • Close:
  • Low:
  • Volume:
  • Date:

News

No News Available

{{item.Body}}



General Overview

About Mesoblast

Mesoblast Limited is a global leader in regenerative medicine. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late stage product candidates. Mesoblast’s allogeneic or ‘off-the-shelf’ cell product candidates target significantly advanced stages of diseases where there are highly unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic & inflammatory disorders and oncology & hematology conditions. 

Product Portfolio

Mesoblast’s proprietary technology platform is based on mesenchymal lineage adult stem cells (MLCs) and underpins all its therapeutic products. Its lead product candidates include MPC-150-IM for congestive heart failure, MPC-06-ID for chronic lower back pain due to moderate degenerative disc disease, MSC-100-IV for steroid refractory acute graft versus host disease (GVHD), and MPC-300-IV for biologic refractory rheumatoid arthritis, and diabetic nephropathy.

All of Mesoblast’s products are allogenic or “off-the-shelf”, meaning stem cells from young healthy adult donors are expanded and used in many unrelated patients.  

Each of Mesoblast’s portfolio of MLC-derived product candidates has its own distinct technical characteristics, target indications, individual reimbursement strategy, separate commercialization potential, and unique partnering opportunities. 

The Company’s proprietary manufacturing processes are designed to enable production at commercial scale with reproducibility and batch-to-batch consistency.

Commercial Strategy

Mesoblast’s products have been prioritized into two tiers. Tier 1 represents the lead programs where the majority of time and resources are focused. Tier 2 programs have the potential to advance to Tier 1 depending on newly-generated data, market opportunity or partnering options. Additionally, the Company has a significant pipeline of earlier-stage programs.

Mesoblast has established strategic relationships with several industry leaders to support clinical development, manufacturing and commercial capabilities. Its partners include Teva Pharmaceutical Industries Ltd, JCR Pharmaceuticals Co. Ltd and Lonza Group. 

Mesoblast has a strong patent portfolio composed of 67 patent families across major potential markets.

Team

Led by Chief Executive Silviu Itescu, a pioneer of stem cell therapeutics, the Mesoblast management team has substantial experience in all aspects of biopharmaceutical development.

Product Candidates Overview

Mesoblast’s MLC-based product candidates have achieved clinically meaningful results in Phase 2 and Phase 3 studies across a broad range of indications, with an extensive patient safety data file.

Understanding and capitalizing on the mechanisms of action of its proprietary MLCs has enabled Mesoblast to develop MLC-based products that target specific disease states. These mechanisms of action include induction of tissue repair, new blood vessel network formation, and immunomodulation.

Lead Product Candidates

MPC-150-IM is Mesoblast’s Phase 3 product candidate partnered with Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) for the treatment of chronic congestive heart failure (CHF). 

A Phase 2 trial in patients with Class II/III (New York Heart Association) CHF has been completed.  Results showed that MPC-150-IM treatment, as compared to control and other dose levels, led to the greatest effects on clinical outcomes. This included significant improvement (reduction) in left ventricular volumes and no heart failure-related major adverse cardiovascular (HF-MACE) events over three years. In advanced (Class II/III) patients, MPC-150-IM had a more pronounced effect.  

Advanced heart failure patients represent a major unmet clinical need despite recent advances in drug therapy.

MPC-06-ID is the Phase 3 product candidate for the treatment of chronic low back pain due to moderate degenerative disc disease (CDLBP). 

In a Phase 2 study, MPC-06-ID treatment resulted in a greater proportion of patients achieving reduced back pain (50% reduction from baseline) compared to patients who did not receive MPC-06-ID (controls). In addition, a clinically significant improvement in back function (15 point Oswestry Disability Index improvement) was reported with no further intervention over 12 months of follow-up. 

A Phase 3 clinical trial is actively enrolling CDLBP patients. Since current treatments for CDLBP focus only on pain relief rather than addressing the underlying degenerative nature of the disease, the Company believes MPC-06-ID could fill an unmet treatment gap for this large population of patients. 

MSC-100-IV is a Phase 3 intravenously-delivered product candidate, which is being developed for the treatment of acute Graft Versus Host Disease (aGVHD) following allogeneic bone marrow transplantation.

Data from a pediatric Expanded Access Program in the United States, from the first 160 children treated with MSC-100-IV for severe, multi-line refractory aGVHD, showed a significant response and survival benefit. 

A pediatric Phase 3 trial for MSC-100-IV has commenced and is actively enrolling patients

Mesoblast’s partner in Japan for aGVHD, JCR Pharmaceuticals Co. Ltd., has filed for Japanese regulatory approval for its aGVHD MSC-based product, JR-031. If successful it will be the first allogenic cell-based product approved in Japan.

MPC-300-IV is an intravenously-delivered immunomodulatory product candidate, which is being developed for the treatment of chronic systemic inflammatory conditions, including biologic-refractory rheumatoid arthritis, and diabetic nephropathy.  

A Phase 2 trial of MPC-300-IV is ongoing in patients with biologic-refractory rheumatoid arthritis, where the first dose cohort has completed recruitment; the second dose cohort is actively enrolling. 

A Phase 2 trial of MPC-300-IV in insufficiently controlled type 2 diabetes patients established the safety of intravenous MPCs up to a dose of 246 million cells. It demonstrated a response on improvement in hemoglobin A1c (HbA1c), the primary measure of glycemic control, for diabetes which may be consistent with an immunomodulatory effect on disease pathogenesis. 

In addition, a Phase 2 trial of MPC-300-IV in patients with diabetic nephropathy has completed recruitment and six months of follow-up.

Mesenchymal Lineage Adult Stem Cells (MLC) Technology Platform

Mesenchymal stem cells are multipotent stromal cells that can differentiate into a variety of cell types, including: osteoblasts (bone cells), chondrocytes (cartilage cells), muscle cells and adipocytes (fat cells).

Mesoblast’s MLC technology platform enables development of a broad product range based on mesenchymal stem cells (MSCs) or distinct cell types derived from or that are the progeny of the earliest precursors of the mesenchymal cell lineage in adult tissues; these cells are known as mesenchymal precursor cells (MPCs). MPCs can be isolated using monoclonal antibodies and are then expanded in culture without differentiation. 

MSCs are defined biologically in culture following density gradient separation from other tissue cell types and following culture by plastic adherence.  MSCs presumably represent culture-expanded in vitro progeny of the undifferentiated MPCs present in vivo. The different functional characteristics of each cell type enable distinct product development for different targeted diseases. 

MLCs are rare cells present around blood vessels in all tissues where they can respond effectively to various signals associated with tissue damage. This response includes the secretion by MLCs of a variety of biomolecules, including growth factors, cytokines, chemokines and immunomodulatory biomolecules that affect various repair mechanisms associated with the maintenance of tissue health. 

Scalable Manufacturing

Manufacturing scale-up is a major focus for Mesoblast in order to meet projected commercial demands and reduce costs for supply. Mesoblast has developed manufacturing processes employing both two dimensional (2D) and three dimensional (3D) bioreactor technologies that they expect will enable production at commercial scale with reproducibility, batch-to-batch consistency and a well-defined potency and release assays. Their manufacturing activities have met stringent criteria set by international regulatory agencies, including the United States Food and Drug Administration.

Strategic Partnerships

Teva Pharmaceutical Industries

Mesoblast is partnered with Teva Pharmaceutical Industries Ltd. for the development and commercialization of its Mesenchymal Precursor Cell (MPC) products in a number of fields, including cardiovascular diseases and neurologic conditions. This strategic alliance provides Mesoblast with a partner who has Phase 3 clinical and regulatory expertise, proven capability to bring products to market, and global distribution strength. The lead product in this alliance is for congestive heart failure. A multi-center, 1730-patient trial is actively recruiting patients across multiple clinical sites in North America. This Phase 3 trial is being conducted by Teva and includes two interim analyses of efficacy and/or safety.

JCR Pharmaceuticals Co. Ltd

Mesoblast has an established relationship with Japan’s JCR Pharmaceuticals Co. Ltd. JCR has been granted an exclusive right in Japan to Mesoblast’s culture-expanded mesenchymal stem cell (MSC) technology for use in conjunction with the treatment for hematologic malignancies using hematopoietic stem cell transplants.  JCR is developing JR-031 for both pediatric and adult graft versus host diseased for adults and children and in 2014 filed for market approval in Japan.

Lonza Group

Mesoblast has an alliance with Lonza Group for clinical and long-term commercial manufacturing requirements of its allogeneic MPC products. This alliance provides Mesoblast with significant commercial advantages, including certainty of capacity to meet long-term global supply of its proprietary MPC products, exclusive access to Lonza’s cell therapy facilities in Singapore, and the potential for a purpose-built manufacturing facility to be built by Lonza to meet Mesoblast’s long-term commercial objectives. Other commercial benefits include the ability to reduce cost of goods and to provide research support for optimized second generation products.

Corporate

Headquartered in Melbourne, Australia, Mesoblast became publicly listed on the Australian Securities Exchange (ASX:MSB) in 2004 and has approximately 120 employees in Australia, USA, Europe and Singapore.

Price History

52 Week High Change from 52 Week High % Change from 52 Week High 52 Week Low Change from 52 Week Low % Change from 52 Week Low
${{quote["Year's High"]}} ${{(quote["Historic Close"] - quote["Year's High"]) | setDecimalCheckForNa}} {{(((quote["Historic Close"] / quote["Year's High"]) - 1) * 100) | setDecimalCheckForNa}}% ${{quote["Year's Low"] | setDecimalCheckForNa}} ${{(quote["Historic Close"] - quote["Year's Low"])| setDecimalCheckForNa}} {{(((quote["Historic Close"] / quote["Year's Low"]) - 1) * 100) | setDecimalCheckForNa}}%
Date Open High Low Close Volume

Dividend Information

Dividend Yield Dividend Yield (5 Yr Avg) ISIN Stock Code (RIC) SEDOL Dividend Currency
{{ratios.Valuation.DivYield_CurTTM.Value | setDecimalCheckForNa}} {{ratios.Valuation.YLD5YAVG.Value | setDecimalCheckForNa}} {{Dividends[0].ISIN}} {{Dividends[0].RIC}} {{Dividends[0].SEDOL}} {{Dividends[0].DividendCurrency != '' ? Dividends[0].DividendCurrency : '-'}}

Year CorpActID DPTD DivAnnDate DivExDate DivPayDate DTMD DivRate DRD DRPrice DTMD DTMD Frank%
{{item.DividendExDate == '00/01/1900' ? '-' : item.DividendExDate}} {{item.CorporateActionsID}} {{item.DividendPaymentTypeDescription}} {{item.DividendAnnoucementDate == '00/01/1900' ? '-' : item.DividendAnnoucementDate}} {{item.DividendExDate == '00/01/1900' ? '-' : item.DividendExDate}} {{item.DividendPayDate == '00/01/1900' ? '-' : item.DividendPayDate}} {{item.DividendTypeMarkerDescription}} {{item.DividendRate != '0' ? item.DividendRate : '-'}} {{item.DividendReinvestmentDeadline == '00/01/1900' ? '-' : item.DividendReinvestmentDeadline}} {{item.DividendReinvestmentPrice != '0' ? item.DividendReinvestmentPrice : '-'}} {{item.DividendTaxMarkerDescription != '' ? item.DividendTaxMarkerDescription : '-'}} {{item.DividendTaxRate != '0' ? item.DividendTaxRate :'-'}} {{item.FrankingPercent != '0' ? item.FrankingPercent : '-'}}

Share Statistics

  Revenue/Share Free Cash Flow Per Share Cash Flow Per Share Book Value Per Share Book Value(tangible) Per Share Cash Per Share
Most Recent Quarter - - - {{ratios['Per share data'].QBVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].QTANBVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].QCSHPS.Value | setDecimalCheckForNa}}
Most Recent Fiscal Year {{ratios['Per share data'].AREVPS.Value | setDecimalCheckForNa}} - {{ratios['Per share data'].ACFSHR.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ABVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ATANBVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ACSHPS.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Per share data'].TTMREVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMFCFSHR.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMCFSHR.Value | setDecimalCheckForNa}} - - -
  Dividend Per Share EPS Normalized EPS Basic Exluding Extraordinary Items EPS Including Extraordinary Items EPS Excluding Extraordinary Items EBITD Per Share
Most Recent Fiscal Year {{ratios['Per share data'].ADIVSHR.Value | setDecimalCheckForNa}} {{ratios['Per share data'].AEPSNORM.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ABEPSXCLXO.Value | setDecimalCheckForNa}} {{ratios['Per share data'].AEPSINCLXO.Value | setDecimalCheckForNa}} {{ratios['Per share data'].AEPSXCLXOR.Value | setDecimalCheckForNa}} -
Trailing 12 Months {{ratios['Per share data'].TTMDIVSHR.Value | setDecimalCheckForNa}} - {{ratios['Per share data'].TTMBEPSXCL.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMEPSINCX.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMEPSXCLX.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMEBITDPS.Value | setDecimalCheckForNa}}
5 Year Average {{ratios['Per share data'].ADIV5YAVG.Value | setDecimalCheckForNa}} - - - - -
Avg Vol(3 month) Avg Vol(10 day) Shares Outstanding Float % Held by Insiders % Held by Institutions Shares Short Shares Ratio Short % of Float Shares Short(prior month)
{{ratios['Price and Volume'].VOL3MAVG.Value | checkForNa}} {{ratios['Price and Volume'].VOL10DAVG.Value | checkForNa}} - - - - - - - -
Common Shareholders Shares Outstanding Shares Issued Float
{{generalInfo.CompanyGeneralInfo.CommonShareholders.Value | checkForNa}} {{sharesIssuedData.SharesOut | abbreviateNumber | checkForNa}} {{sharesIssuedData.SharesIssued | abbreviateNumber | checkForNa}} {{sharesIssuedData.Float | abbreviateNumber | checkForNa}}
Index Code Index name
{{item}} {{generalInfo.IndexMembership[item]}}
N/A N/A
Order Industry Type Code Mnemonic Reported
N/AN/AN/AN/AN/AN/A
{{detail.Order | checkForNa}} {{detail.Description | checkForNa}} {{industry | checkForNa}} {{detail.Code | checkForNa}} {{detail.Mnemonic | checkForNa}}

Valuation Ratios

  P/E excluding extraordinary items P/E Normalized P/E Basic excluding extraordinary items P/E excluding extraordinary items high P/E excluding extraordinary items low P/E including extraordinary items
Most Recent Fiscal Year {{ratios.Valuation.APEEXCLXOR.Value | setDecimalCheckForNa}} {{ratios.Valuation.APENORM.Value | setDecimalCheckForNa}} - - - -
TTM {{ratios.Valuation.PEEXCLXOR.Value | setDecimalCheckForNa}} - {{ratios.Valuation.PEBEXCLXOR.Value | setDecimalCheckForNa}} {{ratios.Valuation.TTMPEHIGH.Value | setDecimalCheckForNa}} {{ratios.Valuation.TTMPELOW.Value | setDecimalCheckForNa}} {{ratios.Valuation.PEINCLXOR.Value | setDecimalCheckForNa}}
  Price to Sales Price to Tangible Book Price to Free Cash Flow per Share Price to Cash Flow per Share Price to Book
Most Recent Fiscal Year {{ratios.Valuation.APR2REV.Value | setDecimalCheckForNa}} {{ratios.Valuation.APR2TANBK.Value | setDecimalCheckForNa}} {{ratios.Valuation.APRFCFPS.Value | setDecimalCheckForNa}} - {{ratios.Valuation.APRICE2BK.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios.Valuation.TTMPR2REV.Value | setDecimalCheckForNa}} - {{ratios.Valuation.TTMPRFCFPS.Value | setDecimalCheckForNa}} {{ratios.Valuation.TTMPRCFPS.Value | setDecimalCheckForNa}} -
Most Recent Quarter - {{ratios.Valuation.PR2TANBK.Value | setDecimalCheckForNa}} - - {{ratios.Valuation.PRICE2BK.Value | setDecimalCheckForNa}}
Dividend Yield - 5 Year Average {{ratios.Valuation.YLD5YAVG.Value | setDecimalCheckForNa}}
Dividend Yield - indicated annual dividend divided by closing price {{ratios.Valuation.YIELD.Value | setDecimalCheckForNa}}
Current Dividend Yield - Common Stock Primary Issue, LTM {{ratios.Valuation.DivYield_CurTTM.Value | setDecimalCheckForNa}}
Net Debt, LFI {{ratios.Valuation.NetDebt_I.Value | setDecimalCheckForNa}}
Net Debt, LFY {{ratios.Valuation.NetDebt_A.Value | setDecimalCheckForNa}}

Financial Strength Ratios

  Current ratio Quick ratio LT debt/equity Total debt/total equity
Most Recent Quarter {{ratios['Financial strength'].QCURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QQUICKRATI.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QLTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QTOTD2EQ.Value | setDecimalCheckForNa}}
Most Recent Fiscal Year {{ratios['Financial strength'].ACURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AQUICKRATI.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ALTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ATOTD2EQ.Value | setDecimalCheckForNa}}
  Payout ratio Current EV/Free Cash Flow Interest coverage Total debt/total equity
Most Recent Fiscal Year {{ratios['Financial strength'].APAYRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].EV2FCF_CurA.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AINTCOV.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ATOTD2EQ.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Financial strength'].TTMPAYRAT.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].EV2FCF_CurTTM.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].TTMINTCOV.Value | setDecimalCheckForNa}} -
Income Statement Revenue EBITD Earnings before taxes Net Income available to common Earnings before taxes Normalized Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding
Most Recent Fiscal Year {{ratios['Income Statement'].AREV.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].AEBITD.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].AEBT.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].ANIAC.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].AEBTNORM.Value | setDecimalCheckForNa}} -
Trailing 12 Months {{ratios['Income Statement'].TTMREV.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].TTMEBITD.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].TTMEBT.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].TTMNIAC.Value | setDecimalCheckForNa}} - {{ratios['Income Statement'].VDES_TTM.Value | setDecimalCheckForNa}}
  Gross Margin Net Profit Margin % Operating Margin Pre Tax Margin Free Operating Cash Flow/Revenue
1st Historical Fiscal Year {{ratios.Margins.AGROSMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.ANPMGNPCT.Value | setDecimalCheckForNa}} {{ratios.Margins.AOPMGNPCT.Value | setDecimalCheckForNa}} {{ratios.Margins.APTMGNPCT.Value | setDecimalCheckForNa}} -
Trailing 12 Months {{ratios.Margins.TTMGROSMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.TTMNPMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.TTMOPMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.TTMPTMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.Focf2Rev_TTM.Value | setDecimalCheckForNa}}
5 Year Average {{ratios.Margins.GROSMGN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.MARGIN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.OPMGN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.PTMGN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.Focf2Rev_AAvg5.Value | setDecimalCheckForNa}}
Risk Ratio Current Ratio Quick Ratio Interest Coverage LT Debt/Equity Total Debt/Total equity
Most Recent Quarter {{ratios['Financial strength'].QCURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QQUICKRATI.Value | setDecimalCheckForNa}} - {{ratios['Financial strength'].QLTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QTOTD2EQ.Value | setDecimalCheckForNa}}
Most Recent Fiscal Year {{ratios['Financial strength'].ACURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AQUICKRATI.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AINTCOV.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ALTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ATOTD2EQ.Value | setDecimalCheckForNa}}
Trailing 12 Months - - {{ratios['Financial strength'].TTMINTCOV.Value | setDecimalCheckForNa}} - -

Management Effectiveness Ratios

Turnover Asset Inventory Receivables
Most Recent Fiscal Year {{ratios['Mgmt Effectiveness'].AASTTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AINVTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].ARECTURN.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Mgmt Effectiveness'].TTMASTTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMINVTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMRECTURN.Value | setDecimalCheckForNa}}
Return on Average Assets EBITD Equity Investment
Most Recent Fiscal Year {{ratios['Mgmt Effectiveness'].AROAPCT.Value | setDecimalCheckForNa}} - {{ratios['Mgmt Effectiveness'].AROEPCT.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AROIPCT.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Mgmt Effectiveness'].TTMROAPCT.Value | setDecimalCheckForNa}} - {{ratios['Mgmt Effectiveness'].TTMROEPCT.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMROIPCT.Value | setDecimalCheckForNa}}
5 Year Average {{ratios['Mgmt Effectiveness'].AROA5YAVG.Value | setDecimalCheckForNa}} - {{ratios['Mgmt Effectiveness'].AROE5YAVG.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AROI5YRAVG.Value | setDecimalCheckForNa}}
Employees Net Income Revenue
Most Recent Fiscal Year {{ratios['Mgmt Effectiveness'].ANIPEREMP.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AREVPEREMP.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Mgmt Effectiveness'].TTMNIPEREM.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMREVPERE.Value | setDecimalCheckForNa}}

Growth Ratios

Growth Rates Revenue % EPS Dividend Revenue/Share Book Value Per Share Capital Spending Net Profit Margin
Most Recent Quarter 1 Year Ago {{ratios.Growth.REVCHNGYR.Value | setDecimalCheckForNa}} {{ratios.Growth.EPSCHNGYR.Value | setDecimalCheckForNa}} - - - - -
5 Years {{ratios.Growth.REVTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.EPSTRENDGR.Value | setDecimalCheckForNa}} - {{ratios.Growth.REVPS5YGR.Value | setDecimalCheckForNa}} {{ratios.Growth.BVTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.CSPTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.NPMTRENDGR.Value | setDecimalCheckForNa}}
3 Years {{ratios.Growth.REVGRPCT.Value | setDecimalCheckForNa}} {{ratios.Growth.EPSGRPCT.Value | setDecimalCheckForNa}} {{ratios.Growth.DIVGRPCT.Value | setDecimalCheckForNa}} - - - -
TTM over TTM {{ratios.Growth.EPSTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.TTMEPSCHG.Value | setDecimalCheckForNa}} - - - - -
CAGR Free Operating Cash Flow Earnings Before Interest, Taxes, Depreciation & Amortization Tangible Book Value Total Debt
5 Year CAGR {{ratios.Growth.FOCF_AYr5CAGR.Value | setDecimalCheckForNa}} {{ratios.Growth.Ebitda_AYr5CAGR.Value | setDecimalCheckForNa}} {{ratios.Growth.TanBV_AYr5CAGR.Value | setDecimalCheckForNa}} {{ratios.Growth.STLD_AYr5CAGR.Value | setDecimalCheckForNa}}
5 Year Interim CAGR - {{ratios.Growth.Ebitda_TTMY5CAGR.Value | setDecimalCheckForNa}} - -

Forecast Ratios

Projected Sales ProjSalesH ProjSalesL ProjSalesNumOfEst ProjSalesPS
{{forecasts.ProjSales | setDecimalCheckForNa}} {{forecasts.ProjSalesH | setDecimalCheckForNa}} {{forecasts.ProjSalesL | setDecimalCheckForNa}} {{forecasts.ProjSalesNumOfEst | setDecimalCheckForNa}} {{forecasts.ProjSalesPS | setDecimalCheckForNa}}
ProjSalesQ ProjSalesQH ProjSalesQL ProjSalesQNumOfEst Price2ProjSales
{{forecasts.ProjSalesQ | setDecimalCheckForNa}} {{forecasts.ProjSalesQH | setDecimalCheckForNa}} {{forecasts.ProjSalesQL | setDecimalCheckForNa}} {{forecasts.ProjSalesQNumOfEst | setDecimalCheckForNa}} {{forecasts.Price2ProjSales | setDecimalCheckForNa}}
ProjEPS ProjEPSHigh ProjEPSLow ProjEPSNumOfEst ProjEPSQ
{{forecasts.ProjEPS | setDecimalCheckForNa}} {{forecasts.ProjEPSH | setDecimalCheckForNa}} {{forecasts.ProjEPSL | setDecimalCheckForNa}} {{forecasts.ProjEPSNumOfEst | setDecimalCheckForNa}} {{forecasts.ProjEPSQ | setDecimalCheckForNa}}
ProjEPSQH ProjEPSQL ProjEPSQNumOfEst ProjPE ProjLTGrowthRate
{{forecasts.ProjEPSQH | setDecimalCheckForNa}} {{forecasts.ProjEPSQL | setDecimalCheckForNa}} {{forecasts.ProjEPSQNumOfEst | setDecimalCheckForNa}} {{forecasts.ProjPE | setDecimalCheckForNa}} {{forecasts.ProjLTGrowthRate | setDecimalCheckForNa}}
TargetPrice EPSActual EPSPrev EPSSurprise EPSSurprisePrc
{{forecasts.TargetPrice | setDecimalCheckForNa}} {{forecasts.EPSActual | setDecimalCheckForNa}} {{forecasts.EPSPrev | setDecimalCheckForNa}} {{forecasts.EPSSurprise | setDecimalCheckForNa}} {{forecasts.EPSSurprisePrc | setDecimalCheckForNa}}
EPSActualQ EPSPrevQ EPSSurpriseQ EPSSurpriseQPrc
{{forecasts.EPSActualQ | setDecimalCheckForNa}} {{forecasts.EPSPrevQ | setDecimalCheckForNa}} {{forecasts.EPSSurpriseQ | setDecimalCheckForNa}} {{forecasts.EPSSurpriseQPrc | setDecimalCheckForNa}}
ProjProfit ProjProfitH ProjProfitL ProjProfitNumOfEst
{{forecasts.ProjProfit | setDecimalCheckForNa}} {{forecasts.ProjProfitH | setDecimalCheckForNa}} {{forecasts.ProjProfitL | setDecimalCheckForNa}} {{forecasts.ProjProfitNumOfEst | setDecimalCheckForNa}}
ProjDPS ProjDPSH ProjDPSL ProjDPSNumOfEst
{{forecasts.ProjDPS | setDecimalCheckForNa}} {{forecasts.ProjDPSH | setDecimalCheckForNa}} {{forecasts.ProjDPSL | setDecimalCheckForNa}} {{forecasts.ProjDPSNumOfEst | setDecimalCheckForNa}}

Financial Reports

Financial Summary

Last Updated: {{generalInfo.TextInfo['Financial Summary'].LastUpdated}}

{{generalInfo.TextInfo['Financial Summary'].Value && generalInfo.TextInfo['Financial Summary'].Value != ''? generalInfo.TextInfo['Financial Summary'].Value: 'No Financial Summary Found.'}}


Accounting Notes
Fiscal Year Ends Most Recent Quarter Transfer agent Auditor Shariah Compliant

{{generalInfo.CompanyGeneralInfo.TotalSharesOut.Data | date:'dd/MM/yyyy' }}

-

- - {{generalInfo.Auditor && generalInfo.Auditor != ''? generalInfo.Auditor : '-'}}
Fiscal Period
Period End Date:
Period Length
Ratios Value
Analyst Footnotes

Last Updated: {{generalInfo.TextInfo['Analyst Footnotes'].LastUpdated}}

{{generalInfo.TextInfo['Analyst Footnotes'].Value && generalInfo.TextInfo['Analyst Footnotes'].Value != '' ? generalInfo.TextInfo['Analyst Footnotes'].Value : 'No Analyst Footnotes Found.'}}



Directors, Officers & Company Executives

Start Date End Date
{{personobject.PersonInformation.Name.Info| getDirectorFullNameIncludingPrefix}}
{{persontitlesobject.Value}}, {{persontitles.Start.Day}}-{{persontitles.Start.Month}}-{{persontitles.Start.Year}} {{persontitles.End.Day}}-{{persontitles.End.Month}}-{{persontitles.End.Year}}
No Directors, Officers & Company Executives Information Found.

Recommendation Statistics

No Recommendation Statistics

Recommendation Statistics
Recommendation Number Of Analysts
{{stats.Recommendation}} {{stats.NumberOfAnalysts}}
I/B/E/S Mean
{{verdict[meanmarker]}} {{analystvotes}} Analysts Mean recommendation from all analysts covering the company on a standardized 5-point scale.
  • Sell
  • Reduce
  • Hold
  • Buy
  • Strong Buy

Past Broker Recommendations

No Past Recommendations

Past Broker Recommendations
  Strong Buy Buy Hold Underperform Sell Total
{{snapshots.Age === 1 ? "1 Week Ago" : (snapshots.Age === 2 ? "30 Days Ago" : (snapshots.Age === 3 ? "60 Days Ago" : (snapshots.Age === 4 ? "90 Days Ago" : "")))}} {{snapshots.Statistics[0].NumberOfAnalysts}} {{snapshots.Statistics[1].NumberOfAnalysts}} {{snapshots.Statistics[2].NumberOfAnalysts}} {{snapshots.Statistics[3].NumberOfAnalysts}} {{snapshots.Statistics[4].NumberOfAnalysts}} {{snapshots.NumberOfRecommendations}}

Target Price

No Target Price

Target Price
Mean {{priceTarget.Mean}}
High {{priceTarget.High}}
Low {{priceTarget.Low}}
Median {{priceTarget.Median}}
Standard Devitation {{priceTarget.StandardDeviation}}
Number Of Estimates {{priceTarget.NumberOfEstimates}}

Videos

No Videos Found

Click here to view video

{{video.summary}}




Contact Info

Mesoblast Limited

Level 38
55 Collins street
Melbourne, VIC
Australia, 3000

Phone: +61 3 9639 6036
Fax: +61 3 9639 6030
Email: info@mesoblast.com
Website: http://www.mesoblast.com

Click here to view the interactive map
Mesoblast Limited Google Map
Mesoblast Limited Google Map

Share Registry

Link Market Services Limited - Click here to view share registry profile

Phone: +61 2 8280 7100
Fax: N/A
Email: info@linkmarketservices.com.au
Website: http://www.linkmarketservices.com.au/

Level 12
680 George Street
Sydney, NSW
AU Australia, 2000


Important Information

This profile was last edited on 02 Feb 2016.

All Financial Data is provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Share Prices nor any independent data provider is liable for any informational errors, omissions or other defects, incompleteness, or delays, or for any actions taken in reliance on Financial Data.

Please read our Terms & Conditions and Disclaimer Statement for further information.

Home

Search

Login

Report a bug